Tomorrow, @hilaryevansnewton.bsky.social chairs a WDC dialogue on treatment access in Europe — and what it will take to get payers to follow regulators. Learn more: bit.ly/4seP96q
In much of Europe, regulators have approved disease-modifying treatments for Alzheimer’s disease — but payers haven’t followed. Next week, @hilaryevansnewton.bsky.social chairs a WDC dialogue on what it will take to change that. Learn more: bit.ly/4seP96q
Lenny Shallcross at #Tau2026 on lessons from the first anti-amyloid treatments: patient voice is patient choice. From the patient perspective, extra time is not modest. The job of this field is to make sure patients get that choice.
At #Tau2026, Lenny Shallcross: by 2030, the community has to be ready for tau treatments. With the first anti-amyloid disease-modifying treatments, the field wasn't ready. We can't let that happen again.
WDC is at #Tau2026 this week, joining the global tau research community to examine where the science is heading and what it means for diagnostics, treatments and care. On Friday, Lenny Shallcross speaks in Session 8: Vision to 2030 for Tau-Based Research.
Announcing the 2026 WDC Summit — “The New Patient: Before Symptoms, After Diagnosis” — Oct. 20 at the Francis Crick Institute, London. An invitation-only gathering of global leaders in dementia science, policy and care. Learn more: bit.ly/40bH0mO
Pooling failed trials with successful ones, then declaring amyloid a dead end, isn’t caution — it’s overreach. In his latest Policy Dispatch, Lenny Shallcross argues the field is asking the right question: how much further can this go? Learn more: bit.ly/3R3rBnm
It's a point Lenny made earlier this week in his later'st Policy Dispatch — that "modest" carries a judgement dressed as a clinical observation, and the call on what's worth it belongs to patients. Read more: bit.ly/3R3rBnm
Dementia science is advancing — but turning breakthroughs into real-world change for patients requires more than research. The WDC, in partnership with @alzassociation.bsky.social, will host "The Public Policy Challenge: From Science to Delivery" alongside #AAIC26. bit.ly/AAICbreakfast2026
Innovation alone won't change patient outcomes — implementation will. The May @alzdemjournals.bsky.social WDC Update captures expert insight on moving Alzheimer's biomarkers from breakthrough to bedside, chaired by Dr. Fiona Carragher of the Alzheimer's Society. Learn more: bit.ly/4uugfYc
